ALEC
USDAlector Inc. Common Stock
Цена в режиме реального времени
График цен
Ключевые показатели
Рыночные показатели
Открытие
$1.400
Максимум
$1.435
Минимум
$1.290
Объем
1.77M
Фундаментальные показатели компании
Рыночная капитализация
133.6M
Отрасль
Биотехнология
Страна
United States
Статистические данные торговли
Средний объем
2.62M
Биржа
NMS
Валюта
USD
52-недельный диапазон
Связанные новости
Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce
Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; Alector cuts 49% of staff.
TD Cowen Downgrades Alector to Hold
TD Cowen analyst Yaron Werber downgrades Alector from Buy to Hold.
Cantor Fitzgerald Downgrades Alector to Neutral
Cantor Fitzgerald analyst Pete Stavropoulos downgrades Alector from Overweight to Neutral.
HC Wainwright & Co. Maintains Buy on Alector, Lowers Price Target to $5
HC Wainwright & Co. analyst Andrew Fein maintains Alector with a Buy and lowers the price target from $10 to $5.
William Blair Downgrades Alector to Market Perform
William Blair analyst Myles Minter downgrades Alector from Outperform to Market Perform.
BTIG Downgrades Alector to Neutral
BTIG analyst Thomas Shrader downgrades Alector from Buy to Neutral.
Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of
Связанные акции
Оставаться в курсе
Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.